Literature DB >> 8050081

Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER.

M H Jeng1, S Y Jiang, V C Jordan.   

Abstract

We have previously demonstrated that transfection of estrogen receptor (ER)-negative human breast cancer MDA-MB-231 (clone 10A) cells with a sense constitutive wildtype ER expression vector regains hormonal responsiveness (Jiang and Jordan, J. Natl. Cancer Inst., 84 (1992) 580-591). We have therefore undertaken studies using stable transfectant S30 cells to determine the function of ER in the regulation of the levels of growth factor mRNAs, an event believed to be mediated via the ER and is important for the paracrine and autocrine regulation of breast cancer cell proliferation. Northern blot analysis demonstrated that 17 beta-estradiol (E2) increased the level of TGF alpha mRNA and decreased the level of TGF beta 2 mRNA. TGF beta 1 and TGF beta 3 mRNA levels were not affected by ER in S30 cells. The addition of anti-estrogen ICI 164,384 blocked the regulation of the mRNA levels of TGF alpha and TGF beta 2 by E2. The expression of these growth factor mRNAs was not affected by E2 or ICI 164,384 in the parental MDA-MB-231 10A and antisense ER transfectant AS23 cells. We demonstrated that the expression of ER in previously ER-negative human breast cancer cells can restore the regulation of growth factor mRNA expression by E2. An increase in TGF alpha and a decrease in TGF beta 2 is associated with an increase in growth of hormone responsive cells. Paradoxically the transfected cells have decreased growth in response to estrogen. Furthermore, these data suggest that other factors in addition to ER are required for TGF beta 1 and TGF beta 3 gene regulation by E2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050081     DOI: 10.1016/0304-3835(94)90001-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

Review 3.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

4.  The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.

Authors:  Zhinong Jiang; Junlan Guo; Jianguo Shen; Mei Jin; Shuduo Xie; Linbo Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-05-03

5.  The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.

Authors:  A S Levenson; D A Tonetti; V C Jordan
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.

Authors:  Nalo Hamilton; Diana Márquez-Garbán; Vei Mah; Gowry Fernando; Yahya Elshimali; Hermes Garbán; David Elashoff; Jaydutt Vadgama; Lee Goodglick; Richard Pietras
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

7.  Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.

Authors:  Susanne Schüler-Toprak; Julia Häring; Elisabeth C Inwald; Christoph Moehle; Olaf Ortmann; Oliver Treeck
Journal:  BMC Cancer       Date:  2016-12-21       Impact factor: 4.430

Review 8.  Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.

Authors:  V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2021-08-16       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.